Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape

被引:162
作者
Salazar-Onfray, Flavio
Lopez, Mercedes N.
Mendoza-Naranjo, Ariadna
机构
[1] Univ Chile, Fac Med, Inst Ciencias Biomed, Programa Disciplinario Inmunol, Santiago, Chile
[2] Univ Chile, Clin Hosp, Res Support Off, Santiago, Chile
关键词
cytokines; IL-10; tumor; melanoma; immunotherapy; antigen presenting cells; tumor immunology;
D O I
10.1016/j.cytogfr.2007.01.015
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The role of cytokines in modulating the formation of new tumors is mediated by their ability to regulate antigen-specific anti-tumor responses and by the activation of non-specific mechanisms, including those involved in the processes of inflammation and innate resistance. Cytokines may influence the growth of tumors by acting directly on tumor cells as growth promoting or growth inhibiting factors or indirectly by attracting inflammatory cell types and affecting angiogenesis. Due to the potency and complexity of cytokine activity against tumor growth, the improvement of cloning techniques and the availability of recombinant forms of different cytokines, a great effort has been made in the recent years to exploit this anti-tumor potential for cancer therapy. This important goal has been difficult to achieve in most cases due to toxicity of most cytokines which could not be dissociated from their anti-tumoral functions. Nevertheless, if well designed, treatment protocols and/or modifications of the cytokine molecules may in some situations augment the anti-tumor effects while limiting the toxicity. One of these molecular approaches could be the design of peptides containing the functional domain of certain cytokines, exemplified by IT9302, a peptide homologous to the functional domain of IL-10, which has demonstrated to increase tumor NK cell sensitivity. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:171 / 182
页数:12
相关论文
共 108 条
[1]   Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I that highly express IL-6 receptor α myeloma cells [J].
Abroun, S ;
Ishikawa, H ;
Tsuyama, N ;
Liu, SQ ;
Li, FJ ;
Otsuyama, K ;
Zheng, X ;
Obata, M ;
Kawano, MM .
BLOOD, 2004, 103 (06) :2291-2298
[2]   UK MEDICAL-RESEARCH-COUNCIL RANDOMIZED, MULTICENTER TRIAL OF INTERFERON-ALPHA-N1 FOR CHRONIC MYELOID-LEUKEMIA - IMPROVED SURVIVAL IRRESPECTIVE OF CYTOGENETIC RESPONSE [J].
ALLAN, NC ;
RICHARDS, SM ;
SHEPHERD, PCA .
LANCET, 1995, 345 (8962) :1392-1397
[3]   Disposition of recombinant human interleukin-10 in subjects with various degrees of renal function [J].
Andersen, SR ;
Lambrecht, LJ ;
Swan, SK ;
Cutler, DL ;
Radwanski, E ;
Affrime, MB ;
Garaud, JJ .
JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (10) :1015-1020
[4]   Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles [J].
Andreola, G ;
Rivoltini, L ;
Castelli, C ;
Huber, V ;
Perego, P ;
Deho, P ;
Squarcina, P ;
Accornero, P ;
Lozupone, F ;
Lugini, L ;
Stringaro, A ;
Molinari, A ;
Arancia, G ;
Gentile, M ;
Parmiani, G ;
Fais, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (10) :1303-1316
[5]   The IFN gamma receptor: A paradigm for cytokine receptor signaling [J].
Bach, EA ;
Aguet, M ;
Schreiber, RD .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :563-&
[6]   Tumor necrosis factor or tumor promoting factor? [J].
Balkwill, F .
CYTOKINE & GROWTH FACTOR REVIEWS, 2002, 13 (02) :135-141
[7]   Inflammation and cancer: back to Virchow? [J].
Balkwill, F ;
Mantovani, A .
LANCET, 2001, 357 (9255) :539-545
[8]   In vivo effects of locally secreted IL-10 on the murine antitumor immune response [J].
Barth, RJ ;
Coppola, MA ;
Green, WR .
ANNALS OF SURGICAL ONCOLOGY, 1996, 3 (04) :381-386
[9]   Cellular responses to interferon-gamma [J].
Boehm, U ;
Klamp, T ;
Groot, M ;
Howard, JC .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :749-795
[10]   ROLE OF INTERFERON-GAMMA IN MEDIATING THE ANTITUMOR EFFICACY OF INTERLEUKIN-12 [J].
BRUNDA, MJ ;
LUISTRO, L ;
HENDRZAK, JA ;
FOUNTOULAKIS, M ;
GAROTTA, G ;
GATELY, MK .
JOURNAL OF IMMUNOTHERAPY, 1995, 17 (02) :71-77